+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dravet Syndrome Drug"

From
From
Dravet Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Dravet Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 60 Pages
  • Global
From
From
Dravet Syndrome Treatment Market 2024-2028 - Product Thumbnail Image

Dravet Syndrome Treatment Market 2024-2028

  • Report
  • June 2024
  • 178 Pages
  • Global
From
From
Dravet Syndrome (DS) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Dravet Syndrome (DS) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
US Dravet Syndrome Market and Competitive Landscape - 2022 - Product Thumbnail Image

US Dravet Syndrome Market and Competitive Landscape - 2022

  • Report
  • August 2022
  • United States
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Dravet Syndrome is a rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures. Treatment of Dravet Syndrome typically involves a combination of antiepileptic drugs, dietary therapies, and other therapies. Within the context of Central Nervous System Drugs, the Dravet Syndrome Drug market is a specialized segment of the larger epilepsy drug market. It is composed of drugs that are specifically designed to treat Dravet Syndrome, as well as drugs that are used off-label to treat the condition. The Dravet Syndrome Drug market is composed of both generic and branded drugs. Some of the companies in the market include GW Pharmaceuticals, Zogenix, Eisai, and UCB. Show Less Read more